The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs

Adeno-associated virus (AAV) vectors are promising modalities of gene therapy to address unmet medical needs. However, anti-AAV neutralizing antibodies (NAbs) hamper the vector-mediated therapeutic effect. Therefore, NAb prevalence in the target population is vital in designing clinical trials with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwakura, Yuji, Baatartsogt, Nemekhbayar, Yamazaki, Shoji, Nagao, Azusa, Amano, Kagehiro, Suzuki, Nobuaki, Matsushita, Tadashi, Sawada, Akihiro, Higasa, Satoshi, Yamasaki, Naoya, Fujii, Teruhisa, Ogura, Taemi, Takedani, Hideyuki, Taki, Masashi, Matsumoto, Takeshi, Yamanouchi, Jun, Sakai, Michio, Nishikawa, Masako, Yatomi, Yutaka, Yada, Koji, Nogami, Keiji, Watano, Ryota, Hiramoto, Takafumi, Hayakawa, Morisada, Kamoshita, Nobuhiko, Kume, Akihiro, Mizukami, Hiroaki, Ishikawa, Shizukiyo, Sakata, Yoichi, Ohmori, Tsukasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661668/
https://www.ncbi.nlm.nih.gov/pubmed/36381300
http://dx.doi.org/10.1016/j.omtm.2022.10.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9661668/
https://www.ncbi.nlm.nih.gov/pubmed/36381300
http://dx.doi.org/10.1016/j.omtm.2022.10.014

Ejemplares similares